标题：FOXO1在膀胱癌组织中的表达及其与临床病理特征和预后的关系

      作者：杨川，王凯    汉川市人民医院泌尿外科，湖北 汉川 431600

      卷次： 2019年30卷4期

      【摘要】 目的 探究叉头框蛋白O1 (FOXO1)在膀胱癌(BC)组织中的表达及其与临床病理特征和预后的关系。方法 选取2013年5月至2014年7月在汉川市人民医院泌尿外科行手术切除的35例膀胱癌组织标本，并选取相应的 35例癌旁(距病灶 1 cm处)正常组织标本作为对照组。收集入试者临床资料，并采用免疫组化法和Western blot法检测FOXO1，采用配对卡方分析不同临床资料患者的FOXO1表达情况。结果 膀胱癌组织、肌层浸润性癌(MIBC)、高/低分化、有淋巴结转移患者的FOXO1阳性表达率分别为88.57%、100.00%、100.00%/100.00%、100.00%，明显高于癌旁组织、浅表性癌(NMIBC)、低度恶性倾向、无淋巴结转移患者的FOXO1阳性表达率(分别为14.29%、73.33%、60.00%、77.78%)，差异均有统计学意义(P<0.05)；对照组正常组织的FOXO1表达为 0.81±0.35，明显低于NMIBC组织、MIBC组织的 1.16±0.54、1.90±0.46，差异均有统计学意义(P<0.05)；NMIBC组织FOXO1的表达为1.16±0.54，明显低于MIBC组织的表达的1.90±0.46，差异有统计学意义(P<0.05)；在不同FOXO1表达患者中，40个月存活率比较中，阴性表达的膀胱癌患者生存率为50.00%，略高于阳性表达组的32.26%，但差异无统计学意义(P>0.05)。结论 FOXO1在不同临床病理特征的BC患者中表现有差异，以膀胱癌组织、MIBC、高/低分化、有淋巴结转移患者的FOXO1表达阳性率较高，但FOXO1阳性及阴性表达患者生存时间相当。
      【关键词】 叉头框蛋白O1；膀胱癌；预后；病理特征；免疫组化法；表达
      【中图分类号】 R737.14 【文献标识码】 A 【文章编号】 1003—6350（2019）04—437—04F

OXO1 expression in bladder cancer tissues and its correlation with clinical pathological characteristics andprognosis.
YANG Chuan, WANG Kai. Department of Urology Surgery, the People's Hospital of Hanchuan City, Hanchuan431600, Hubei, CHINA
【Abstract】 Objective To explore the expression of FOXO1 in bladder cancer and its relationship with clinico-pathologic features and prognosis. Methods A total of 35 cases of bladder cancer tissue samples from the patients whoadmitted to Department of Urology Surgery of the People's Hospital of Hanchuan City from May 2013 to July 2014,were collected as the research subjects. Meantime, the corresponding 35 cases of normal tissue samples were collected asthe control group. Immunohistochemistry and Western blot were used to detect FOXO1, and paired chi-square was usedto analyze FOXO1 expression in patients with different clinical data. Results The positive expression rates of FOXO1in bladder cancer, muscular invasive bladder cancer (MIBC), high/low differentiation and lymph node metastasis were88.57% , 100.00% , 100.00%/100.00% and 100.00% , respectively, which were significantly higher than corresponding14.29%, 73.33%, 60.00%, 77.78% in the tissue adjacent to carcinoma, non-muscle invasive bladder cancer (NMIBC),low-grade malignant tendency, lymph node metastasis (P<0.05). The expression of FOXO1 in normal tissues of the con-trol group was 0.81±0.35, which was significantly lower than 1.16±0.54 and 1.90±0.46 in NMIBC tissue and MIBC tis-sue (P<0.05). The expression of FOXO1 in NMIBC tissue was 1.16±0.54, which was significantly lower than 1.90±0.46of MIBC organization (P<0.05). For 40-month survival rate comparison in the patients with different FOXO1 expres-sion, the negative expression of patients with bladder cancer survival rate was 50.00%, which was slightly higher than32.26% in the positive expression group (P<0.05). Conclusion FOXO1 has an existing differential in patients with dif-ferent clinical pathology, and in the case of bladder cancer tissue, MIBC, high/low differentiation, and lymph node metas-tasis, FOXO1 has higher positive expression rates. It was found that that survival time of FOXO1 positive and negativepatients had no significant difference.
      【Key words】 FOXO1; Bladder cancer; Prognosis; Clinicopathologic features; Immunohistochemical method; Ex-pression